Open AccessThis article is
- freely available
Evolution of Biologics Screening Technologies
MedImmune Ltd, Milstein Building, Granta Park, Cambridge CB21 6GH, UK
* Author to whom correspondence should be addressed.
Received: 5 February 2013; in revised form: 23 April 2013 / Accepted: 8 May 2013 / Published: 14 May 2013
(This article belongs to the Special Issue Biologics
Abstract: Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought.
Keywords: high throughput screening; assay technologies; therapeutic antibodies
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Cariuk, P.; Gardener, M.J.; Vaughan, T.J. Evolution of Biologics Screening Technologies. Pharmaceuticals 2013, 6, 681-688.
Cariuk P, Gardener MJ, Vaughan TJ. Evolution of Biologics Screening Technologies. Pharmaceuticals. 2013; 6(5):681-688.
Cariuk, Peter; Gardener, Matthew J.; Vaughan, Tristan J. 2013. "Evolution of Biologics Screening Technologies." Pharmaceuticals 6, no. 5: 681-688.